JAMP Pharma Corporation is recalling mislabelled bottles from lot PTC5140A of Venlafaxine extended release (XR) capsules after one bottle labelled to contain 37.5 mg capsules was found to contain 150 mg capsules. Only the mislabelled bottles are being recalled. Venlafaxine XR is a prescription drug used to relieve symptoms of major depressive disorder and anxiety caused by generalized anxiety disorder, social anxiety disorder and panic disorder. If pharmacists did not recognize the error, they may have repackaged and dispensed pharmacy bottles labelled as containing 37.5 mg capsules, but instead contained 150 mg capsules. This error could lead to patients taking a higher dose than prescribed. Venlafaxine XR 37.5 mg capsules have a grey cap and pink body, with "RVn" printed on the cap and "37.5" printed on the body. Venlafaxine XR 150 mg capsules are caramel in colour with "RVn" printed on the cap and "150" printed on the body. Venlafaxine XR de JAMP (capsules de 37,5 mg) Venlafaxine XR de JAMP (capsules de 150 mg) Accidently taking more than the prescribed dose can lead to serious side effects. Side effects requiring immediate medical attention include allergic reactions, gastrointestinal bleeding (signs include vomiting blood, passing blood in stool or black stool), seizures, heart rhythm problems, blurred vision, eye pain and severe headache. A sudden dose increase may also cause chills, high blood pressure, decreased appetite, nausea, agitation, dizziness, sleepiness, tremor, yawning or sweating. The Department is monitoring the company's recall and will inform the public if any new health risks are identified.